Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Document › Details

Silence Therapeutics plc. (4/18/19). "Press Release: Silence Therapeutics Appoints Dr. Rob Quinn as Chief Financial Officer". London.

Organisations Organisation Silence Therapeutics plc (AIM: SLN)
  Group Silence Therapeutics (Group)
  Organisation 2 GlaxoSmithKline plc (LSE: GSK, NYSE: GSK)
  Group GlaxoSmithKline (GSK) (Group)
Product Product RNA-based therapeutic
Persons Person Quinn, Rob (Silence Therapeutics 201904– CFO joined 2017 before GSK)
  Person 2 Solomon, David Horn (Silence Therapeutics 201807– CEO before Zealand Pharma + Bionor Pharma + Akari Therapeutics)
     


Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce the appointment of Rob Quinn as full time Chief Financial Officer, effective immediately.

Dr. Quinn has served as the Interim Chief Financial Officer of Silence since January 2019, having been the Head of Financial Planning and Analysis at the Company for the two years prior to this. He has a wealth of both financial and scientific experience and before joining Silence he held a senior role at GSK, as Area Finance Director for Africa & Developing Countries. Dr. Quinn is a Chartered Accountant and qualified at Deloitte, including time spent working in corporate finance advisory within the life sciences sector. He also holds a PhD in Biochemistry from the University of Manchester. Dr. Quinn will not be appointed to the Board of Directors.

David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented: “I’m very pleased that Rob will serve as full time Chief Financial Officer and on behalf of the Board I would like to formally welcome him to this role. Rob’s scientific and financial skills, alongside his commercial acumen make him an asset to the Silence team. During his time at the Company he has continued to play an important role in building the business, with a keen appreciation for how we will grow in the future”.


Enquiries:

Silence Therapeutics plc
Dr David Horn Solomon, Chief Executive Officer
Tel: +44 (0)20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker)
James Steel/Oliver Jackson
Tel: +44 (0)20 7418 8900

European IR Consilium Strategic Communications
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
Tel: +44 (0) 20 3709 5700

US IR Westwicke Partners
Peter Vozzo
peter.vozzo@westwicke.com
Tel: +1 (443) 213-0505


About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: https://www.silence-therapeutics.com/

   
Record changed: 2019-09-23

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Silence Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px




» top